Analyst Ratings for Rhythm Pharmaceuticals (RYTM)
RYTM Rating Summary
RYTM Price Target Summary
- Highest: $176.00 (Citizens)
- Lowest: $102.00 (Leerink Partners)
- Average: $136.33
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$136.33 (+45.8%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 91%
Avg. $ Target:
$136.33 (+45.8%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 91%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/18/2026 | RBC Capital » Updated 2/27/2026 |
Lisa Walter | New Coverage | Outperform (N/A) |
140.00 (145.00) |
102.53 (93.52) |
-8.79% | Details |
| 11/25/2025 | Citi | Samantha Semenkow | New Coverage | Buy (N/A) |
136.00 (N/A) |
101.74 (93.52) |
-8.08% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
